275 related articles for article (PubMed ID: 18097503)
1. Effect of an extract of Ganoderma lucidum in men with lower urinary tract symptoms: a double-blind, placebo-controlled randomized and dose-ranging study.
Noguchi M; Kakuma T; Tomiyasu K; Kurita Y; Kukihara H; Konishi F; Kumamoto S; Shimizu K; Kondo R; Matsuoka K
Asian J Androl; 2008 Jul; 10(4):651-8. PubMed ID: 18097503
[TBL] [Abstract][Full Text] [Related]
2. Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms.
Noguchi M; Kakuma T; Tomiyasu K; Yamada A; Itoh K; Konishi F; Kumamoto S; Shimizu K; Kondo R; Matsuoka K
Asian J Androl; 2008 Sep; 10(5):777-85. PubMed ID: 18097505
[TBL] [Abstract][Full Text] [Related]
3. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
4. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement.
Mills IW; Crossland A; Patel A; Ramonas H
Eur Urol; 2007 Aug; 52(2):503-9. PubMed ID: 17343981
[TBL] [Abstract][Full Text] [Related]
6. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
[TBL] [Abstract][Full Text] [Related]
7. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
[TBL] [Abstract][Full Text] [Related]
8. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
9. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
10. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
11. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
[TBL] [Abstract][Full Text] [Related]
12. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.
Marberger M; Chartier-Kastler E; Egerdie B; Lee KS; Grosse J; Bugarin D; Zhou J; Patel A; Haag-Molkenteller C
Eur Urol; 2013 Mar; 63(3):496-503. PubMed ID: 23098762
[TBL] [Abstract][Full Text] [Related]
13. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
Paick SH; Meehan A; Lee M; Penson DF; Wessells H
J Urol; 2005 Mar; 173(3):903-7. PubMed ID: 15711315
[TBL] [Abstract][Full Text] [Related]
14. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
[TBL] [Abstract][Full Text] [Related]
15. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
McVary KT; Roehrborn CG; Kaminetsky JC; Auerbach SM; Wachs B; Young JM; Esler A; Sides GD; Denes BS
J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
[TBL] [Abstract][Full Text] [Related]
16. [Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: a randomized, double-blind, placebo-controlled, parallel-group, dose response study].
Tsukamoto T; Endo Y; Narita M
Hinyokika Kiyo; 2009 Apr; 55(4):209-14. PubMed ID: 19462826
[TBL] [Abstract][Full Text] [Related]
17. Use of selenium-silymarin mix reduces lower urinary tract symptoms and prostate specific antigen in men.
Vostalova J; Vidlar A; Ulrichova J; Vrbkova J; Simanek V; Student V
Phytomedicine; 2013 Dec; 21(1):75-81. PubMed ID: 24012146
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of Ganoderma lucidum (lingzhi) and San Miao San supplementation in patients with rheumatoid arthritis: a double-blind, randomized, placebo-controlled pilot trial.
Li EK; Tam LS; Wong CK; Li WC; Lam CW; Wachtel-Galor S; Benzie IF; Bao YX; Leung PC; Tomlinson B
Arthritis Rheum; 2007 Oct; 57(7):1143-50. PubMed ID: 17907228
[TBL] [Abstract][Full Text] [Related]
19. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
Tsukamoto T; Masumori N; Rahman M; Crane MM
Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
Nitti VW; Dmochowski R; Sand PK; Forst HT; Haag-Molkenteller C; Massow U; Wang J; Brodsky M; Bavendam T
J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
